Allspring Global Investments Holdings LLC grew its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS – Get Rating) by 802.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,218 shares of the medical equipment provider's stock after buying an additional 1,083 shares during the period. Allspring Global Investments Holdings LLC's holdings in BioLife Solutions were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds have also made changes to their positions in BLFS. Wipfli Financial Advisors LLC purchased a new stake in BioLife Solutions during the third quarter worth approximately $29,000. Point72 Hong Kong Ltd acquired a new stake in BioLife Solutions during the first quarter worth approximately $36,000. Lazard Asset Management LLC purchased a new stake in shares of BioLife Solutions during the 1st quarter worth approximately $45,000. Ancora Advisors LLC acquired a new position in shares of BioLife Solutions in the 1st quarter valued at $90,000. Finally, KBC Group NV purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at $36,000. 89.82% of the stock is owned by institutional investors and hedge funds.
Get BioLife Solutions alerts:BioLife Solutions Price Performance
Shares of NASDAQ:BLFS opened at $25.27 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.76 and a current ratio of 3.68. BioLife Solutions, Inc. has a one year low of $10.40 and a one year high of $29.92. The company has a 50-day simple moving average of $20.72 and a 200-day simple moving average of $21.60. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of -10.19 and a beta of 1.86.
BioLife Solutions (NASDAQ:BLFS – Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The medical equipment provider reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03). BioLife Solutions had a negative net margin of 67.70% and a negative return on equity of 7.50%. The company had revenue of $40.75 million for the quarter, compared to analysts' expectations of $41.63 million. On average, analysts predict that BioLife Solutions, Inc. will post -0.63 EPS for the current year.Insider Transactions at BioLife Solutions
In related news, CMO Todd Berard sold 6,500 shares of BioLife Solutions stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $25.04, for a total value of $162,760.00. Following the transaction, the chief marketing officer now directly owns 119,265 shares in the company, valued at approximately $2,986,395.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, COO Greef Roderick De sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, November 14th. The stock was sold at an average price of $23.86, for a total value of $477,200.00. Following the completion of the sale, the chief operating officer now directly owns 96,719 shares of the company's stock, valued at approximately $2,307,715.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Todd Berard sold 6,500 shares of the company's stock in a transaction on Wednesday, January 18th. The stock was sold at an average price of $25.04, for a total value of $162,760.00. Following the transaction, the chief marketing officer now directly owns 119,265 shares in the company, valued at approximately $2,986,395.60. The disclosure for this sale can be found here. Insiders sold 113,718 shares of company stock worth $2,466,734 over the last 90 days. 3.30% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the stock. StockNews.com upgraded shares of BioLife Solutions to a "sell" rating in a research note on Monday, November 21st. Stephens dropped their price target on BioLife Solutions to $31.00 in a research note on Wednesday, November 16th.
BioLife Solutions Company Profile
(Get Rating)
BioLife Solutions, Inc engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services.
Recommended Stories
- Get a free copy of the StockNews.com research report on BioLife Solutions (BLFS)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.